Mergeworthrx — SPAC Merger (October 2014)
26 slides from Mergeworthrx's SPAC merger presentation, Oct 23, 2014
Slide 1: Business Combination with AeroCare Holdings, Inc.
MERGEWorTHRX Corp. BUSINESS COMBINATION WITH AEROCARE HOLDINGS, INC. El AeroCare INVESTOR PRESENTATION Octoser 2014
Slide 2: Disclaimer
Disclaimer her MergeWorthRx Corp (*MWRX") nor any of its respective affiliates makes any repres Contalned nts presetaon, The Sele pupae ofthe presrtation te aust persons ecng. transaction discussed herein and isnot intended to be all inclusive oto contain all he informa presenta 5 shall ures ta * of
Slide 3: Transaction Overview
Transaction Overview "or the “Company”? in an all tock transa > vot on, combloed company exacted otc on ro forma enterprise ae appronnatly 212mm and eulty value of $88mm (suming no MergeWorth shareholder cransaction redemptions 58 share price and dea-related closing costs/expenses of approximately $
Slide 4: Transaction Rationale
Transaction Rati i i i i Therapy (RT) / Durable Medical Equipment nt (OME) Sector traded stock, nsolidation Public Market Entry Multiple sdent Target Acquisition er Current Comparable Company ‘Multiple Paid ‘Trading Range Drive Customer Loyalty on all levels ‘Access to New Technologies Broaden Servi
Slide 5: AeroCare Investment Highlights
AeroCare Investment Highlights = Compelling valuation and transaction structure v v YAllstock transaction Chon Obstet Plenary ease COPD" Obstructive Sleep Apnea (“O: . Multiple wowth oF port ron of which are expected to ore In G8 201) gy Operating leverage - scalable platform and IT investments =P l
Slide 6: Transaction Valuation
Transaction Valuation Transaction Valuation (Pots ond shores outstondng in millon, exept er shore doa) At Closing With Full Earnout Shares Outancing 22.009 25.597 int in Trust per Share $8.36 $8.36 Equity Value @ $8.36 / share $184.0 $214.0 AeroCare Debt” 872 ° 87.2 (59.4) (59.4) Implied Enterprise
Slide 7: Ownership
Ownership Mergent Public shares Insiders ai a (1). AeroCore’scurtent ownership based on ~32.7mm total shares outstanding, which includes “Emm eption (2) Proforma owner sumes ne sree redenotens frist oan de rea i losing ond are subject to achievement of upto 3:yer Bro Form Adjusted EBITDA earnout tar
Slide 8: Comparable Companies
Comparable Companies Currently, there are no publicly-traded neue Therapy (RT) / Durable Medical E: mpany believes the companies listed bel pment (DME) p most relevant publicly-traded eaaanies comer ee on me following characteristics: Home Health, je ic (Sinmilions except shore price dato) Closing P
Slide 9: Metrics
Metri 2014E EV/EBITDA” 2015E EV/EBITDA” I] I Iii | | | | I Vth 508 dein DaVita. Ooo LB wh Bi say Davita. nfo Qoewwe ime LTM EBITDA Margins as of June 30, 2014 EBITDA CAGR (2012-2015E) I | I if i _ a: = wae Bierce pidyita, @ 0% © Baron F DiVita,” @ 20% wenfeb | odoinn ae erecta ayaa eras 1 Sense ee r
Slide 10: Implied Stock Price Based on 2014E Pro Forma Adjusted EBITDA Multiple Expansion
Implied Stock Price Based on 2014E Pro Forma Adjusted EBITDA Multiple Expansion BITDA® Mul Implied AeroCare’s Stock Price at Various 2014E Pro Forma Adjust. $16.00 $14.00 $12.00 + $10.00 $8.36 $8.00 $6.00 $4.00 $2.00 $0.00 5.9% 6.5x 7.0x 8.0x 9.0x 10.0x 2014E Pro Forma Adjusted EBITDA Multiple (2) 2
Slide 11: AeroCare Overview
AeroCare Overview AeroCare is a top 10 provider of U.S. home oxygen and sleep therapy services with 176 locations in 20 states AeroCare is one of the fastest organic and total growth Respiratory Therapy (RT) / Durable Medical Equipment (DME) companies among leading sector participants Founded in lat
Slide 12: AeroCare Opportunity
AeroCare Opportunity AeroCare represents a unique opportunity to enter the Durable Medical Equipment (DME) / = Industry Evolution: Medicare payment reform has forced the industry to embrace a distribution / logistics focus over service " Visible Reimbursement Process: Competitive Bidding has provide
Slide 13: AeroCare CEO Steve Griggs and Executive Team
AeroCare CEO Steve Griggs and Executive Team Steve Griggs Chairman & CEO Management Founded AeroCare in 2000 25+ years in RT/DME sector (15 years in home infusion) Former President of RoTech Medical (pre-sale to Integrated Medical System); generated rapid growth through a combination of acquisitions
Slide 14: Diverse Reimbursement Profile
Diverse Reimbursement Profile 2012 2013 YTD 6/30/14 Medicare 58.9% Medicare accounted for 54% of revenue as of June 2014 YTD compared to 59% in 2013 and 62% in 2012 (a) includes Medicare Advontone 14
Slide 15: AeroCare is Focused on Two Key Medical Issues with Attractive Growth Profiles
AeroCare is Focused on Two Key Medical Issues with Attractive Growth Profiles hh, Chronic Obstructive Pulmonary Disease (“CopD”) ———4 Ow —_, Obstructive Sleep Apnea (“OSA”) ———__ #3 Chronic Disease 45 Million People in U.S. with m3 ee a ee $114 billion market in the U.S. Growing at 7%+ annually 31 l
Slide 16: Competitive Bidding Program (CBP) Overview
Competitive Bidding Program (“CBP”) Overview Round 1 and Round 1 Recompete Results = 1,217 contracts awarded to 356 individual 997 contracts awarded to 282 individual suppliers suppliers in 9 competitive bidding areas (“CBAs”), serving 620 locations Multiple winners for each product category given C
Slide 17: Increased Compliance Requirements Driving Complexity
Increased Compliance Requirements Driving Complexity a 7 COPD Reimbursement Changes Waiting on Physician Documentation Waiting on ropery Documented Physkian Notes Patients in Medial Review Waiting on Physician Documentation for Recert Waiting on Physician Documentation for Continued Use and Benefit
Slide 18: Well capitalized and managed providers will likely emerge as consolidators and winners
Well capitalized and managed providers that remain willing to invest for growth will likely emerge as consolidators and winners = “Mom and Pop” entities challenged as cost and complexity of business have increased ~ Providers need capital, management expertise, critical mass and internal growth to s
Slide 19: Growth Strategy
Growth Strategy Overall macroeconomic factors such as patient growth and regulatory and reimbursement pressure, has resulted in industry consolidation, which creates significant opportunities for large providers like AeroCare Ea AeroCare © Continue to Open logical invest in IT efor infrastructure C)
Slide 20: Organic Patient Growth Supplemented by Selective Acquisitions
Organic Patient Growth Supplemented by Selective Acquisitions mate 70000 sq oncenter 3c voretneabys @» ives iam 26,181 2002 2003» 2004» 2005-2006 -«« 2007 «2008S 2009» «201020112012, 2013 Jun-14 ‘Previous Year Patients Acquired Patients m Organic Patients AeroCare
Slide 21: Acquisition Opportunities Across the Spectrum
Acquisition Opportunities Across the Spectrum "90% of providersin the U.S. have <$10MM of revenue Track record of identifying/acquiring targets and integrating them in the existing AeroCare business model ~ Over 50 acquisitions since 2006 = Time-tested, disciplined approach tothe dlgence and integra
Slide 22: Potential to Accelerate Organic Growth Through Targeted Initiatives
Potential to Accelerate Organic Growth Through Targeted Initiatives Additional Products & Services ig Referral Sources * Currently exploring numerous avenues to add products and services to sell through existing referral channels: Leverage improving physician ordering function to deliver more produc
Slide 23: Investments in IT Will Continue to Improve Operating Margins
Investments in IT Will Continue to Improve Operating Margins As industry transitions from service to distribution focus, investments in IT infrastructure will drive efficiencies by creating an electronic connection between the physician's office and AeroCare ws cr ws ws Billing * Engaged with Bright
Slide 24: Summary Historical Income Statement
Summary Historical Income Statement Pro Forma as Adjusted Income Statement 2012 — June 30, 2014 YTD (Sin milion) Fiscal Year Three Months ‘Six Months Ended December 31, Ended June 30, Ended June 30, 2012 2013 2013 2014") 2013 2014" Net Revenue si14s $132.4 $325 $412 $62.4 $80.5 % growth 83% 15.7% NA
Slide 25: Pro Forma Adjusted EBITDA Reconciliation
Pro Forma Adjusted EBITDA Reconciliation Pro Forma as Adjusted EBITDA Reconciliation 2012 — June 30, 2014 YTD (Sinmilions) Fiscal Year Three Months Six Months Ended December 31, Ended June 30, Ended June 30, 2012 2013 2013 2018 ro Forma Adjusted EBITDA Reconciliation: GAAP Net Income S16 Su7 Interes
Slide 26: Unaudited Balance Sheet as of June 30, 2014
Unaudited Balance Sheet as of June 30, 2014 s and Shareholders’ Eq! {(Sinmitons) Current Assets: Current Liabilities: Cash and Cash Equivalents $0.1 Accounts Payable $10.0 Accounts Receivable, net 25.1 Accrued Expenses and Other Current Liabilities 5.6 Inventory, 6.3 Due to Sellers 21 Prepaid & Othe